Rituximab Anti-CD20 Monoclonal Antibody Therapy in Non-Hodgkin’s Lymphoma: Safety and Efficacy of Re-Treatment
Top Cited Papers
- 17 September 2000
- journal article
- clinical trial
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 18 (17), 3135-3143
- https://doi.org/10.1200/jco.2000.18.17.3135
Abstract
PURPOSE: This phase II trial investigated the safety and efficacy of re-treatment with rituximab, a chimeric anti-CD20 monoclonal antibody, in patients with low-grade or follicular non-Hodgkin’s ly...Keywords
This publication has 28 references indexed in Scilit:
- Phase I/II Trial of IDEC-Y2B8 Radioimmunotherapy for Treatment of Relapsed or Refractory CD20+B-Cell Non-Hodgkin's LymphomaJournal of Clinical Oncology, 1999
- Single-Agent Monoclonal Antibody Efficacy in Bulky Non-Hodgkin's Lymphoma: Results of a Phase II Trial of RituximabJournal of Clinical Oncology, 1999
- Treatment of Patients With Low-Grade B-Cell Lymphoma With the Combination of Chimeric Anti-CD20 Monoclonal Antibody and CHOP ChemotherapyJournal of Clinical Oncology, 1999
- Adjuvant chemotherapy with CEF versus CMF for node-positive breast cancer.Journal of Clinical Oncology, 1998
- Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.Journal of Clinical Oncology, 1998
- Interleukin-6–Induced Inhibition of Multiple Myeloma Cell Apoptosis: Support for the Hypothesis That Protection Is Mediated Via Inhibition of the JNK/SAPK PathwayBlood, 1998
- Chimeric Anti-CD20 (IDEC-C2B8) Monoclonal Antibody Sensitizes a B Cell Lymphoma Cell Line to Cell Killing by Cytotoxic DrugsCancer Biotherapy & Radiopharmaceuticals, 1997
- A Predictive Model for Aggressive Non-Hodgkin's LymphomaNew England Journal of Medicine, 1993
- Generation of monoclonal antibodies for in vivo approachesInternational Journal of Radiation Applications and Instrumentation. Part B. Nuclear Medicine and Biology, 1991
- Mouse/human chimeric monoclonal antibody in man: kinetics and immune response.Proceedings of the National Academy of Sciences, 1989